

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.ispto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/757,333	01/09/2001	Samuel I. Achilefu	MRD-67	.5506
26875 7	7590 05/12/2003			
•	RRON & EVANS, LLP		EXAMI	NER
2700 CAREW TOWER 441 VINE STREET CINCINNATI, OH 45202			JONES, DA	MERON
			ART UNIT	PAPER NUMBER
			1616	19
			DATE MAILED: 05/12/2003	′ (

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)	_			
Office Action Summary		09/757,333	ACHILEFU ET AL.				
		Examiner	Art Unit	_			
	•	D. L. Jones	1616				
-	The MAILING DATE of this communication app	<u> </u>					
Period fo	or Reply		·				
THE - Exte after - If the - If NO - Failu - Any	ORTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. e period for reply specified above is less than thirty (30) days, a repl o period for reply is specified above, the maximum statutory period ree to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, ly within the statutory minimul will expire SIX a, cause the application to be	may a reply be timely filed n of thirty (30) days will be considered timely. (6) MONTHS from the mailing date of this communication.				
1)⊠	Responsive to communication(s) filed on 29.	January 2003 .					
2a) <u></u> □	This action is FINAL . 2b)⊠ Th	nis action is non-final					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Dispositi	ion of Claims						
•	Claim(s) <u>1-20</u> is/are pending in the application.						
_	4a) Of the above claim(s) is/are withdrawn from consideration.						
	Claim(s) is/are allowed.						
	Claim(s) <u>1,2,4,5,7-15,18 and 19</u> is/are rejected.						
	Claim(s) <u>3,6,16,17 and 20</u> is/are objected to.						
	Claim(s) are subject to restriction and/o	or election requireme	nt.				
·· _	The specification is objected to by the Examine	ar.	• *				
	The drawing(s) filed on <u>09 January 2001</u> is/are:		abjected to by the Everginer				
10)[2]	Applicant may not request that any objection to the		·				
11) 🗆 .	The proposed drawing correction filed on		•				
, _	If approved, corrected drawings are required in re		•				
12) 🔲	The oath or declaration is objected to by the Ex	•					
Priority u	under 35 U.S.C. §§ 119 and 120						
	Acknowledgment is made of a claim for foreign	n priority under 35 U.	S.C. § 119(a)-(d) or (f).				
a)[☐ All b)☐ Some * c)☐ None of:						
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
* S	3. Copies of the certified copies of the prior application from the International Buse the attached detailed Office action for a list	reau (PCT Rule 17.2	?(a)).				
14) 🗌 A	acknowledgment is made of a claim for domesti	c priority under 35 U	.S.C. § 119(e) (to a provisional application).				
)	• •					
Attachmen	_	-					
2) 🔲 Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) Z	5) 🔲 Not	erview Summary (PTO-413) Paper No(s) tice of Informal Patent Application (PTO-152) er:				

Art Unit: 1616

APPLICANT'S INVENTION

1. Applicant's invention is directed to compounds, compositions, and uses thereof comprising the formula as set forth in independent claims 1, 4, and 18.

RESPONSE TO APPLICANT'S ELECTION

2. Applicant's election with traverse of Group I directed to compounds, compositions, and uses thereof wherein W5 and X5 are CR1R2 in Paper No. 18, filed 3/6/03, is acknowledged. In addition, acknowledgment of the species wherein W5 and X5 = C(CH22OH)2; Y5 = (CH)2-CONH-Bm; Z5 = (CH2)2CONH-Dm; A3 = single bond; A3. B3, C3, and D3 = 6-membered carbocyclic ring; a5 = 1; R58 = galactose; R59-R66 = H; Bm = octreotate; and Dm = bombesin. The traversal is on the ground(s) that the restriction is improper because all the claims are directed to the structure designated as formula 3 and all the claimed compounds have the same utility. This is found nonpersuasive because (1) while it is noted that the claims are directed to compounds. compositions, and uses thereof comprising formula 3, it is also noted that depending upon the variable definitions assigned to W5 and X5, the core structure changes such that there is no common core from one group of species to another. For example, the core for compounds and composition wherein both W5 and X5 = CR1R2 is very different from a core wherein both W5 and X5 are sulfur. Thus, separate searching and consideration of the prior art is necessary for each group of species since one group of compounds/compositions neither anticipates nor renders obvious the other group. Hence, the Examiner would be required to conduct a burdensome search in order to

Art Unit: 1616

search the full scope of the claims since various searches would be necessary.

Furthermore, just for clarification of the record, it should be noted that each group set forth by the Examiner in the restriction requirement encompasses compounds, compositions, and uses thereof. The restriction requirement is still deemed proper and is therefore made FINAL.

Note: The search was expanded over the full scope of Group I. Thus, it should be noted that the search was not expanded to any other of the groups as set forth in the restriction requirement mailed1/29/03, Paper No. 17.

DOUBLE PATENTING REJECTION

3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Art Unit: 1616

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4. Claims 1, 2, 4, 5, 7-15, 18, and 19 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-15 of U.S. Patent No. 6,180,086. Although the conflicting claims are not identical, they are not patentably distinct from each other because both groups of claims are directed to compounds, compositions, and uses thereof having the formula as set forth in claim 1 of the instant invention wherein (a) W5 and X5 are CR1R2 and (b)Y5 and Z5 are (CH2)a-NR3R4 or CH2(CH2OCH2)b-CH2NR3R4. The claims differ in that the claims of the instant invention encompass species wherein Y5 and/or Z5 is selected from the group consisting of a peptide, protein, cell, antibody, antibody fragment, saccharide, glycopeptide, peptidomimetic, drug, drug mimic, hormone, chelating agent, radioactive or non-radioactive metal complex, or an echogenic agent.

CLAIM OBJECTIONS

5. Claims 3, 6, 16, 17, and 20 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Art Unit: 1616

COMMENTS/NOTES

It should be noted that no prior art has been cited against Applicant's elected 6.

Page 5

Group I. However, Applicant must address and overcome the double patenting

rejection. In particular, the claims are distinguished over the prior art of record because

the prior art neither anticipates nor renders obvious compounds, compositions, and

uses thereof encompassed by Group I as set forth above.

Note: Applicant is respectfully requested to cancel the claims directed to the

non-elected inventions.

7. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to D. L. Jones whose telephone number is (703) 308-4640.

The examiner can normally be reached on Mon.-Fri. (alternate Mon.), 6:45 a.m. - 4:15

p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Jose' Dees can be reached on (703) 308-4628. The fax phone numbers

for the organization where this application or proceeding is assigned are (703) 308-4556

for regular communications and (703) 308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or

proceeding should be directed to the receptionist whose telephone number is (703) 308-

1235.

Primary Examiner

Art Unit 1616

May 5, 2003